CIK 0001738021 · Non-accelerated filer<br>Smaller reporting company
Compass Therapeutics, Inc.
Sign in to watch- Ticker
- CMPX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-500-8099
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Former names
- Olivia Ventures, Inc.
- Open-market buys, last 90 days
- $21,250
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$21,250. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-11 | GORDON CARL L Director | Purchase | +64,700 | $1.79 | $116K | 14,690,178 |
| 2022-05-11 | ORBIMED ADVISORS LLC Director | Purchase | +64,700 | $1.79 | $116K | 14,690,178 |
| 2022-05-10 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Purchase | +27,836 | $1.80 | $50K | 5,153,303 |
| 2022-05-10 | ORBIMED ADVISORS LLC Director | Purchase | +24,447 | $1.60 | $39K | 14,625,478 |
| 2022-05-10 | GORDON CARL L Director | Purchase | +24,447 | $1.60 | $39K | 14,625,478 |
| 2022-05-09 | ORBIMED ADVISORS LLC Director | Purchase | +90,712 | $1.56 | $142K | 14,601,031 |
| 2022-05-09 | GORDON CARL L Director | Purchase | +90,712 | $1.56 | $142K | 14,601,031 |
| 2022-05-06 | ORBIMED ADVISORS LLC Director | Purchase | +10,200 | $1.63 | $17K | 14,510,319 |
| 2022-05-06 | GORDON CARL L Director | Purchase | +10,200 | $1.63 | $17K | 14,510,319 |
| 2022-04-26 | GRAY MARY ANN Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2022-04-26 | Chiniara Ellen Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2022-02-18 | Ferneau Philip Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2022-02-18 | GORDON CARL L Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2022-02-18 | Kaplan Brett Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2022-02-18 | SQUINTO STEPHEN P Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2022-02-18 | Kalled Susan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2022-02-18 | Bisker-Leib Vered Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2022-02-18 | Schuetz Thomas J. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +700,000 | 700,000 | ||
| 2022-02-17 | Schuetz Thomas J. Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +700,000 | 700,000 | ||
| 2022-02-17 | Bisker-Leib Vered Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 |
Page 6 of 8 · 143 trades